Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Keller, Michael D  [Clear All Filters]
2024
Keller MD, Hanley PJ, Chi Y-Y, Aguayo-Hiraldo P, Dvorak CC, Verneris MR, Kohn DB, Pai S-Y, Saldaña BJDávila, Hanisch B, et al. Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment. Nat Commun. 2024;15(1):3258.
Khoury R, Grimley MS, Nelson AS, Leemhuis T, Cancelas JA, Cook E, Wang YZ, Heyenbruch D, Bollard CM, Keller MD, et al. Third-party virus specific T cells for the treatment of double stranded DNA viral reactivation and PTLD after solid organ transplant. Am J Transplant. 2024.
2023
Le Voyer T, Parent AV, Liu X, Cederholm A, Gervais A, Rosain J, Nguyen T, Lorenzo MPerez, Rackaityte E, Rinchai D, et al. Autoantibodies against type I IFNs in humans with alternative NF-κB pathway deficiency. Nature. 2023.
Galletta TJ, Lane A, Lutzko C, Leemhuis T, Cancelas JA, Khoury R, Wang YZM, Hanley PJ, Keller MD, Bollard CM, et al. Third party and patient-specific donor-derived virus-specific T cells demonstrate similar efficacy and safety for management of viral infections after hematopoietic stem cell transplant in children and young adults. Transplant Cell Ther. 2023.
2022
Durkee-Shock J, Zhang A, Liang H, Wright H, Magnusson J, Garabedian E, Marsh RA, Sullivan KE, Keller MD. Morbidity, Mortality, and Therapeutics in Combined Immunodeficiency: Data from the USIDNET Registry. J Allergy Clin Immunol Pract. 2022.
Rubinstein JD, Lutzko C, Leemhuis T, Zhu X, Pham G, Ray LM, Thomas S, Dourson C, Wilhelm J, Lane A, et al. Scheduled Administration of Virus-Specific T cells for Viral Prophylaxis After Pediatric Allogeneic Stem Cell Transplant. Blood Adv. 2022.
2019
Fatic A, Zhang N, Keller MD, Hanley PJ. The pipeline of antiviral T-cell therapy: what's in the clinic and undergoing development. Transfusion. 2019.